Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Nové biomarkery a akutní poškození ledvin: nastal čas pro jejich klinické využití?

Cruz DN, de Cal M, Garzotto F, Perazella MA, Lentini P, Corradi V, Piccinni P, Ronco C.

Jazyk čeština Země Česko

Perzistentní odkaz   https://www.medvik.cz/link/bmc10020048

PURPOSE: Neutrophil gelatinase-associated lipocalin (NGAL) is a useful marker for acute kidney injury (AKI), particularly when the timing of renal insult is known. However, its performance in an adult critical care setting has not been well described. We performed this study to estimate the diagnostic accuracy of plasma NGAL for early detection of AKI and need for renal replacement therapy (RRT) in an adult intensive care unit (ICU). METHODS: We enrolled 307 consecutive adult patients admitted to a general medical-surgical ICU; 301 were included in the final analysis. Serial blood samples were analyzed for plasma NGAL using a standardized clinical platform. The primary outcome was AKI, defined as an increase in creatinine of at least 50% from baseline or a reduction in urine output to <0.5 ml/kg/h for >6 h. RESULTS: Of 301 patients, 133 (44%) had AKI during their ICU stay. Plasma NGAL was a good diagnostic marker for AKI development within the next 48 h (area under ROC 0.78, 95% CI 0.65-0.90), and for RRT use (area under ROC 0.82, 95% CI 0.70-0.95). Peak plasma NGAL concentrations increased with worsening AKI severity (R = 0.554, P < 0.001). CONCLUSIONS: Plasma NGAL is a useful early marker for AKI in a heterogeneous adult ICU population, in which the timing of renal insult is largely unknown. It allows the diagnosis of AKI up to 48 h prior to a clinical diagnosis based on AKI consensus definitions. Additionally, it predicts need for RRT and correlates with AKI severity. Early identification of high risk patients may allow potentially beneficial therapies to be initiated early in the disease process before irreversible injury occurs.

000      
00000naa 2200000 a 4500
001      
bmc10020048
003      
CZ-PrNML
005      
20111210183055.0
008      
100909s2010 xr e cze||
009      
AR
040    __
$a ABA008 $b cze $c ABA008 $d ABA008 $e AACR2
041    0_
$a cze $b eng
044    __
$a xr
100    1_
$a Cruz DN,
245    10
$a Nové biomarkery a akutní poškození ledvin: nastal čas pro jejich klinické využití? / $c Cruz DN, de Cal M, Garzotto F, Perazella MA, Lentini P, Corradi V, Piccinni P, Ronco C.
314    __
$a Department of Nephrology, Dialysis and Transplantation, St Bortolo Hospital, Vicenza dinnacruzmd@yahoo.com
520    9_
$a PURPOSE: Neutrophil gelatinase-associated lipocalin (NGAL) is a useful marker for acute kidney injury (AKI), particularly when the timing of renal insult is known. However, its performance in an adult critical care setting has not been well described. We performed this study to estimate the diagnostic accuracy of plasma NGAL for early detection of AKI and need for renal replacement therapy (RRT) in an adult intensive care unit (ICU). METHODS: We enrolled 307 consecutive adult patients admitted to a general medical-surgical ICU; 301 were included in the final analysis. Serial blood samples were analyzed for plasma NGAL using a standardized clinical platform. The primary outcome was AKI, defined as an increase in creatinine of at least 50% from baseline or a reduction in urine output to <0.5 ml/kg/h for >6 h. RESULTS: Of 301 patients, 133 (44%) had AKI during their ICU stay. Plasma NGAL was a good diagnostic marker for AKI development within the next 48 h (area under ROC 0.78, 95% CI 0.65-0.90), and for RRT use (area under ROC 0.82, 95% CI 0.70-0.95). Peak plasma NGAL concentrations increased with worsening AKI severity (R = 0.554, P < 0.001). CONCLUSIONS: Plasma NGAL is a useful early marker for AKI in a heterogeneous adult ICU population, in which the timing of renal insult is largely unknown. It allows the diagnosis of AKI up to 48 h prior to a clinical diagnosis based on AKI consensus definitions. Additionally, it predicts need for RRT and correlates with AKI severity. Early identification of high risk patients may allow potentially beneficial therapies to be initiated early in the disease process before irreversible injury occurs.
650    _2
$a financování organizované $7 D005381
650    _2
$a proteiny akutní fáze $7 D000209
650    _2
$a dospělí $7 D000328
650    _2
$a senioři $7 D000368
650    _2
$a biologické markery $x krev $7 D015415
650    _2
$a kritický stav $7 D016638
650    _2
$a časná diagnóza $7 D042241
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a lidé $7 D006801
650    _2
$a jednotky intenzivní péče $7 D007362
650    _2
$a akutní poškození ledvin $x diagnóza $x epidemiologie $x patofyziologie $7 D058186
650    _2
$a lipokaliny $x krev $7 D054834
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    _2
$a prospektivní studie $7 D011446
650    _2
$a protoonkogenní proteiny $x krev $7 D011518
650    _2
$a náhrada funkce ledvin $7 D017582
650    _2
$a senzitivita a specificita $7 D012680
651    _2
$a Itálie $x epidemiologie $7 D007558
700    1_
$a Cal, M. de
700    1_
$a Garzotto, F.
700    1_
$a Perazella, M. A.
700    1_
$a Lentini, P.
700    1_
$a Corradi, V.
700    1_
$a Piccinni, P.
700    1_
$a Ronco, C.
773    0_
$w MED00012709 $t Postgraduální nefrologie $g Roč. 8, č. 2 (2010), s. 20 $x 1214-178X
787    18
$w bmc10020049 $i Recenze v: $t Komentář [k článku Nové biomarkery a akutní poškození ledvin: nastal čas pro jejich klinické využití?]
856    41
$u https://www.postgradualninefrologie.cz/download/format/pdf/id/156/ $y plný text volně přístupný
910    __
$a ABA008 $b B 2318 $c 893 $y 7
990    __
$a 20100830113932 $b ABA008
991    __
$a 20110128160305 $b ABA008
999    __
$a ok $b bmc $g 769071 $s 633010
BAS    __
$a 3
BMC    __
$a 2010 $b 8 $c 2 $d 20 $m Postgraduální nefrologie $x MED00012709
LZP    __
$a 2010-24/mkme

Najít záznam